Year |
Citation |
Score |
2021 |
Jarvi NL, Balu-Iyer SV. Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 33523413 DOI: 10.1007/s40259-020-00465-4 |
0.362 |
|
2018 |
Dingman R, Balu-Iyer SV. Immunogenicity of Protein Pharmaceuticals. Journal of Pharmaceutical Sciences. PMID 30599169 DOI: 10.1016/J.Xphs.2018.12.014 |
0.381 |
|
2018 |
Shenoy GN, Loyall J, Berenson CS, Kelleher RJ, Iyer V, Balu-Iyer SV, Odunsi K, Bankert RB. Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. Journal of Immunology (Baltimore, Md. : 1950). PMID 30446565 DOI: 10.4049/Jimmunol.1801041 |
0.31 |
|
2018 |
Glassman FY, Balu-Iyer SV. Subcutaneous Administration of Lyso-Phosphatidylserine Nanoparticles Induces Immunological Tolerance Towards Factor VIII in a Hemophilia A Mouse Model. International Journal of Pharmaceutics. PMID 29981412 DOI: 10.1016/J.Ijpharm.2018.07.018 |
0.496 |
|
2018 |
Glassman FY, Schneider JL, Ramakrishnan R, Dingman RK, Ramanathan M, Bankert RB, Balu-Iyer SV. Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher. Journal of Pharmaceutical Sciences. PMID 29649469 DOI: 10.1016/J.Xphs.2018.03.027 |
0.431 |
|
2018 |
Turner MR, Balu-Iyer SV. Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. Journal of Pharmaceutical Sciences. PMID 29336981 DOI: 10.1016/J.Xphs.2018.01.007 |
0.354 |
|
2017 |
Schneider JL, Dingman RK, Balu-Iyer SV. Lipidic Nanoparticles Comprising of Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease. Journal of Pharmaceutical Sciences. PMID 29102549 DOI: 10.1016/J.Xphs.2017.10.038 |
0.464 |
|
2016 |
Schneider JL, Balu-Iyer SV. Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease. Journal of Pharmaceutical Sciences. PMID 27488899 DOI: 10.1016/J.Xphs.2016.06.018 |
0.445 |
|
2016 |
Ramakrishnan R, Balu-Iyer SV. Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model. Journal of Pharmaceutical Sciences. PMID 27431011 DOI: 10.1016/J.Xphs.2016.06.008 |
0.354 |
|
2016 |
Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-Factor VIII antibodies in Hemophilia A mice. Biopharmaceutics & Drug Disposition. PMID 27418232 DOI: 10.1002/Bdd.2023 |
0.757 |
|
2016 |
Shetty KA, Merricks EP, Raymer R, Rigsbee N, Nichols TC, Balu-Iyer SV. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs. Journal of Pharmaceutical Sciences. PMID 27372547 DOI: 10.1016/J.Xphs.2016.05.023 |
0.434 |
|
2015 |
Fathallah AM, Chiang M, Mishra A, Kumar S, Xue L, Middaugh R, Balu-Iyer SV. The Effect of Small Oligomeric Protein Aggregates on the Immunogenicity of Intravenous and Subcutaneous Administered Antibodies. Journal of Pharmaceutical Sciences. PMID 26228094 DOI: 10.1002/Jps.24592 |
0.39 |
|
2015 |
Kelleher RJ, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, Iyer V, Fathallah AM, Berenson CS, Wallace PK, Tario J, Odunsi K, Bankert RB. Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunology Research. 3: 1269-78. PMID 26112921 DOI: 10.1158/2326-6066.Cir-15-0086 |
0.339 |
|
2015 |
Ramakrishnan R, Davidowitz A, Balu-Iyer SV. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice. Journal of Pharmaceutical Sciences. 104: 2451-6. PMID 26038127 DOI: 10.1002/Jps.24513 |
0.388 |
|
2015 |
Fathallah AM, Balu-Iyer SV. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics. Journal of Pharmaceutical Sciences. 104: 301-6. PMID 25411114 DOI: 10.1002/Jps.24277 |
0.444 |
|
2015 |
Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. Journal of Pharmaceutical Sciences. 104: 388-95. PMID 24700333 DOI: 10.1002/Jps.23963 |
0.769 |
|
2014 |
Gaitonde P, Purohit VS, Balu-Iyer SV. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 66: 157-162. PMID 25459532 DOI: 10.1016/J.Ejps.2014.10.010 |
0.812 |
|
2014 |
Fathallah AM, Ramakrishnan R, Balu-Iyer SV. O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells. Journal of Pharmaceutical Sciences. 103: 3457-63. PMID 25266204 DOI: 10.1002/jps.24173 |
0.325 |
|
2014 |
Kosloski MP, Shetty KA, Wakabayashi H, Fay PJ, Balu-Iyer SV. Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo. The Aaps Journal. 16: 1038-45. PMID 24934295 DOI: 10.1208/S12248-014-9627-2 |
0.72 |
|
2014 |
Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharmaceutics & Drug Disposition. 35: 154-63. PMID 24259187 DOI: 10.1002/Bdd.1880 |
0.807 |
|
2013 |
Fathallah AM, Bankert RB, Balu-Iyer SV. Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective. The Aaps Journal. 15: 897-900. PMID 23856740 DOI: 10.1208/S12248-013-9510-6 |
0.382 |
|
2013 |
Gaitonde P, Ramakrishnan R, Chin J, Kelleher RJ, Bankert RB, Balu-Iyer SV. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. The Journal of Biological Chemistry. 288: 17051-6. PMID 23649621 DOI: 10.1074/Jbc.C112.396325 |
0.8 |
|
2013 |
Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. Journal of Pharmaceutical Sciences. 102: 2380-94. PMID 23620343 DOI: 10.1002/Jps.23566 |
0.763 |
|
2012 |
Trummer BJ, Iyer V, Balu-Iyer SV, O'Connor R, Straubinger RM. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. Journal of Pharmaceutical Sciences. 101: 2763-76. PMID 22581704 DOI: 10.1002/Jps.23180 |
0.763 |
|
2012 |
Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. Journal of Pharmaceutical Sciences. 101: 2055-65. PMID 22388918 DOI: 10.1002/Jps.23091 |
0.801 |
|
2012 |
Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. The Aaps Journal. 14: 35-42. PMID 22173945 DOI: 10.1208/S12248-011-9309-2 |
0.82 |
|
2012 |
Bhansali SG, Balu-Iyer SV, Morris ME. Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. Journal of Pharmaceutical Sciences. 101: 852-9. PMID 22030745 DOI: 10.1002/Jps.22795 |
0.309 |
|
2012 |
Peng A, Pisal DS, Doty A, Balu-Iyer SV. Phosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranes. Chemistry and Physics of Lipids. 165: 15-22. PMID 22024173 DOI: 10.1016/J.Chemphyslip.2011.10.002 |
0.764 |
|
2012 |
Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII. Journal of Pharmaceutical Sciences. 101: 48-55. PMID 21953409 DOI: 10.1002/Jps.22746 |
0.796 |
|
2012 |
Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharmaceutical Research. 29: 490-9. PMID 21887597 DOI: 10.1007/S11095-011-0578-3 |
0.312 |
|
2011 |
Pisal DS, Balu-Iyer SV. Phospholipid binding lowers immunogenicity of human recombinant factor VIII in von Willebrand factor knockout mice. Thrombosis and Haemostasis. 105: 1115-8. PMID 21475771 DOI: 10.1160/Th10-09-0628 |
0.799 |
|
2011 |
Gaitonde P, Balu-Iyer SV. In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Methods in Molecular Biology (Clifton, N.J.). 716: 267-80. PMID 21318912 DOI: 10.1007/978-1-61779-012-6_16 |
0.783 |
|
2011 |
Kosloski MP, Peng A, Varma PR, Fathallah AM, Miclea RD, Mager DE, Balu-iyer SV. Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. Drug Delivery. 18: 246-54. PMID 21114461 DOI: 10.3109/10717544.2010.536269 |
0.804 |
|
2011 |
Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clinical Immunology (Orlando, Fla.). 138: 135-45. PMID 21094627 DOI: 10.1016/J.Clim.2010.10.006 |
0.787 |
|
2010 |
Pisal DS, Balu-Iyer SV. Phospholipid binding improves plasma survival of factor VIII. Thrombosis and Haemostasis. 104: 1073-5. PMID 20838749 DOI: 10.1160/Th10-06-0422 |
0.812 |
|
2010 |
Peng A, Straubinger RM, Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. The Aaps Journal. 12: 473-81. PMID 20517659 DOI: 10.1208/S12248-010-9207-Z |
0.779 |
|
2010 |
Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. Journal of Pharmaceutical Sciences. 99: 2557-75. PMID 20049941 DOI: 10.1002/Jps.22054 |
0.77 |
|
2010 |
Rao G, Iyer V, Kosloski MP, Pisal DS, Shin E, Middaugh CR, Balu-Iyer SV. Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics. Journal of Pharmaceutical Sciences. 99: 1697-706. PMID 19798762 DOI: 10.1002/Jps.21938 |
0.782 |
|
2009 |
Themistou E, Singh I, Shang C, Balu-Iyer SV, Alexandridis P, Neelamegham S. Application of fluorescence spectroscopy to quantify shear-induced protein conformation change. Biophysical Journal. 97: 2567-76. PMID 19883600 DOI: 10.1016/J.Bpj.2009.08.023 |
0.335 |
|
2009 |
Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. Journal of Pharmaceutical Sciences. 98: 4480-4. PMID 19499565 DOI: 10.1002/Jps.21765 |
0.784 |
|
2009 |
Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. The Aaps Journal. 11: 424-31. PMID 19499345 DOI: 10.1208/S12248-009-9119-Y |
0.795 |
|
2008 |
Korotchkina LG, Ramani K, Balu-Iyer SV. Folding considerations for therapeutic protein formulations. Progress in Molecular Biology and Translational Science. 83: 255-70. PMID 19186256 DOI: 10.1016/S0079-6603(08)00606-5 |
0.355 |
|
2008 |
Ramani K, Purohit V, Miclea R, Gaitonde P, Straubinger RM, Balu-Iyer SV. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. Journal of Pharmaceutical Sciences. 97: 3753-64. PMID 18300296 DOI: 10.1002/Jps.21266 |
0.777 |
|
2008 |
Ramani K, Miclea RD, Purohit VS, Mager DE, Straubinger RM, Balu-Iyer SV. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. Journal of Pharmaceutical Sciences. 97: 1386-98. PMID 17705286 DOI: 10.1002/Jps.21102 |
0.823 |
|
2007 |
Miclea RD, Varma PR, Peng A, Balu-Iyer SV. Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochimica Et Biophysica Acta. 1768: 2890-8. PMID 17936245 DOI: 10.1016/J.Bbamem.2007.08.001 |
0.821 |
|
2007 |
Miclea RD, Purohit VS, Balu-Iyer SV. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. The Aaps Journal. 9: E251-9. PMID 17907766 DOI: 10.1208/Aapsj0902028 |
0.818 |
|
Show low-probability matches. |